Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Petroni

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 17, 2010
Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccinesCraig L Slingluff, Gina R Petroni, Mark E Smolkin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 25, 2005
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanomaKimberly A Chianese-Bullock, Jennifer Pressley, Courtney Garbee, et al.
Cancer Immunology, Immunotherapy : CII|November 20, 2015
A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sitesCraig L Slingluff, Gina R Petroni, Walter C Olson, et al.
Cancer Immunology, Immunotherapy : CII|August 15, 2016
Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastasesIleana S Mauldin, Nolan A Wages, Anne M Stowman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2004
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed scheduleCraig L Slingluff, Gina R Petroni, Galina V Yamshchikov, et al.
Cancer Immunology, Immunotherapy : CII|August 15, 2016
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastasesIleana S Mauldin, Nolan A Wages, Anne M Stowman, et al.
Journal for Immunotherapy of Cancer|January 22, 2021
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)Craig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cellsCraig L Slingluff, Gina R Petroni, Galina V Yamshchikov, et al.
Journal for Immunotherapy of Cancer|December 1, 2023
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinomaMatthew H G Katz, Gina R Petroni, Todd Bauer, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 17, 2010
Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccinesCraig L Slingluff, Gina R Petroni, Mark E Smolkin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 25, 2005
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanomaKimberly A Chianese-Bullock, Jennifer Pressley, Courtney Garbee, et al.
Cancer Immunology, Immunotherapy : CII|November 20, 2015
A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sitesCraig L Slingluff, Gina R Petroni, Walter C Olson, et al.
Cancer Immunology, Immunotherapy : CII|August 15, 2016
Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastasesIleana S Mauldin, Nolan A Wages, Anne M Stowman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2004
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed scheduleCraig L Slingluff, Gina R Petroni, Galina V Yamshchikov, et al.
Cancer Immunology, Immunotherapy : CII|August 15, 2016
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastasesIleana S Mauldin, Nolan A Wages, Anne M Stowman, et al.
Journal for Immunotherapy of Cancer|January 22, 2021
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)Craig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cellsCraig L Slingluff, Gina R Petroni, Galina V Yamshchikov, et al.
Journal for Immunotherapy of Cancer|December 1, 2023
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinomaMatthew H G Katz, Gina R Petroni, Todd Bauer, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.
Pageof 13